CompanyCGEMNasdaqCambridge, MA

Cullinan Therapeutics Inc.

Cullinan Therapeutics develops T cell engagers for autoimmune diseases and cancer.

SEC EDGAR ClinicalTrials.gov cullinantherapeutics.com

8-KSep 24Latest SEC filing, period to Sep 24

Sep 24Latest story

September 2026

Cullinan Therapeutics outlines fourth-quarter 2026 data plans across three T cell engager programs

Sep 24Clinical readoutCLN-049 CLN-978

August 2026

Zipalertinib combo hits PFS endpoint in Phase 3 lung cancer trial

Aug 12Clinical readoutCullinan Therapeutics Inc.

Cullinan reports Q2 2026 results, outlines T cell engager trial timelines

Aug 6Quarterly updateCullinan Therapeutics Inc.

July 2026

Cullinan Therapeutics registers Phase 1b/2a trial of velinotamig in ITP and wAIHA

Jul 31Trial updateCullinan Therapeutics Inc.

Cullinan Therapeutics registers Phase 1b trial of CLN-049 with azacitidine, venetoclax in AML

Jul 23Trial updateazacitidine CLN-049